Korytnikov Roman, Nostro Maria Cristina
Department of Physiology, University of Toronto, Toronto, ON M5S 1A8, Canada; McEwen Centre for Regenerative Medicine, Toronto, ON M5G 1L7, Canada; Toronto General Research Institute, Department of Experimental Therapeutics, University Health Network, Toronto, ON M5G 1L7, Canada.
Department of Physiology, University of Toronto, Toronto, ON M5S 1A8, Canada; McEwen Centre for Regenerative Medicine, Toronto, ON M5G 1L7, Canada; Toronto General Research Institute, Department of Experimental Therapeutics, University Health Network, Toronto, ON M5G 1L7, Canada.
Methods. 2016 May 15;101:56-64. doi: 10.1016/j.ymeth.2015.10.017. Epub 2015 Oct 27.
Generation of pancreatic β-cells from human pluripotent stem cells (hPSCs) has enormous importance in type 1 diabetes (T1D), as it is fundamental to a treatment strategy based on cellular therapeutics. Being able to generate β-cells, as well as other mature pancreatic cells, from human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) will also enable the development of platforms that can be used for disease modeling and drug testing for a variety of pancreas-associated diseases, including cystic fibrosis. For this to occur, it is crucial to develop differentiation strategies that are robust and reproducible across cell lines and laboratories. In this article we describe two serum-free differentiation protocols designed to generate specific pancreatic lineages from hPSCs. Our approach employs a variety of cytokines and small molecules to mimic developmental pathways active during pancreatic organogenesis and allows for the in vitro generation of distinct pancreatic populations. The first protocol is designed to give rise to polyhormonal cells that have the potential to differentiate into glucagon-producing cells. The second protocol is geared to generate multipotent pancreatic progenitor cells, which harbor the potential to generate all pancreatic lineages including: monohormonal endocrine cells, acinar, and ductal cells.
从人多能干细胞(hPSC)生成胰腺β细胞在1型糖尿病(T1D)治疗中具有极其重要的意义,因为这是基于细胞疗法的治疗策略的基础。能够从人胚胎干细胞(hESC)和人诱导多能干细胞(hiPSC)生成β细胞以及其他成熟胰腺细胞,也将推动可用于多种胰腺相关疾病(包括囊性纤维化)疾病建模和药物测试平台的开发。要实现这一点,开发在不同细胞系和实验室中稳健且可重复的分化策略至关重要。在本文中,我们描述了两种无血清分化方案,旨在从hPSC生成特定的胰腺谱系。我们的方法采用多种细胞因子和小分子来模拟胰腺器官发生过程中活跃的发育途径,并允许在体外生成不同的胰腺细胞群。第一个方案旨在产生具有分化为产生胰高血糖素细胞潜力的多激素细胞。第二个方案旨在生成多能胰腺祖细胞,其具有产生所有胰腺谱系细胞的潜力,包括单激素内分泌细胞、腺泡细胞和导管细胞。